Logo image of SRRA

Sierra Oncology Inc (SRRA) Stock Fundamental Analysis

NASDAQ:SRRA - Nasdaq - US82640U4040 - Common Stock

54.99  +0.02 (+0.04%)

After market: 54.99 0 (0%)

Fundamental Rating

2

Taking everything into account, SRRA scores 2 out of 10 in our fundamental rating. SRRA was compared to 568 industry peers in the Biotechnology industry. While SRRA seems to be doing ok healthwise, there are quite some concerns on its profitability. SRRA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SRRA has reported negative net income.
SRRA Yearly Net Income VS EBIT VS OCF VS FCFSRRA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -20M -40M -60M -80M

1.2 Ratios

Industry RankSector Rank
ROA -36.67%
ROE N/A
ROIC -30.38%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SRRA Yearly ROA, ROE, ROICSRRA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SRRA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SRRA Yearly Profit, Operating, Gross MarginsSRRA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 -5K -10K -15K -20K -25K

More info and screens

4

2. Health

2.1 Basic Checks

SRRA has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
Compared to 1 year ago, SRRA has more shares outstanding
There is no outstanding debt for SRRA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SRRA Yearly Shares OutstandingSRRA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M
SRRA Yearly Total Debt VS Total AssetsSRRA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

2.2 Solvency

SRRA has an Altman-Z score of 38.91. This indicates that SRRA is financially healthy and has little risk of bankruptcy at the moment.
SRRA has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Altman-Z 38.91
ROIC/WACC-3.13
WACC9.71%
SRRA Yearly LT Debt VS Equity VS FCFSRRA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 21.27 indicates that SRRA has no problem at all paying its short term obligations.
SRRA has a Quick Ratio of 21.27. This indicates that SRRA is financially healthy and has no problem in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 21.27
Quick Ratio 21.27
SRRA Yearly Current Assets VS Current LiabilitesSRRA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

SRRA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -7.29%.
SRRA shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-7.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

SRRA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.88% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y31.62%
EPS Next 2Y20.36%
EPS Next 3Y26.06%
EPS Next 5Y14.88%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SRRA Yearly Revenue VS EstimatesSRRA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 200M 400M 600M 800M 1B
SRRA Yearly EPS VS EstimatesSRRA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 -100 -200 -300 -400

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SRRA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SRRA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SRRA Price Earnings VS Forward Price EarningsSRRA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA -10.5
SRRA Per share dataSRRA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

A more expensive valuation may be justified as SRRA's earnings are expected to grow with 26.06% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.36%
EPS Next 3Y26.06%

More info and screens

0

5. Dividend

5.1 Amount

SRRA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Sierra Oncology Inc

NASDAQ:SRRA (6/30/2022, 8:00:01 PM)

After market: 54.99 0 (0%)

54.99

+0.02 (+0.04%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-06 2022-05-06/bmo
Earnings (Next)08-04 2022-08-04/amc
Inst Owners1.64%
Inst Owner Change0%
Ins Owners25.13%
Ins Owner Change0%
Market Cap1.34B
Analysts76
Price Target56.1 (2.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 5.13
P/tB N/A
EV/EBITDA -10.5
EPS(TTM)-6.77
EYN/A
EPS(NY)-3.94
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS10.71
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.67%
ROE N/A
ROCE N/A
ROIC -30.38%
ROICexc N/A
ROICexgc -30.38%
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3Y0%
ROICexcg growth 5Y0%
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.02
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 21.27
Quick Ratio 21.27
Altman-Z 38.91
F-Score3
WACC9.71%
ROIC/WACC-3.13
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.22%
EPS Next Y31.62%
EPS Next 2Y20.36%
EPS Next 3Y26.06%
EPS Next 5Y14.88%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A